Free tool
FAERS Monitor: Lybalvi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213378 or its brand name (Lybalvi, Olanzapine, Samidorphan L-Malate). Reports on generic versions are filed under their own applications.
Reports
1,687
Serious
418
25% of reports
Hospitalization
187
Death reported
18
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use306
- contraindicated product administered139
- weight increased91
- dizziness89
- drug withdrawal syndrome77
- insomnia76
- nausea70
- weight decreased68
- vomiting64
- feeling abnormal61
- somnolence59
- fatigue56
- sedation56
- decreased appetite53
- anxiety50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2019 | 1 |
| 2021 | 51 |
| 2022 | 360 |
| 2023 | 355 |
| 2024 | 322 |
| 2025 | 338 |
| 2026 | 259 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,472 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contraindicated product administeredSignal | 139 | 57.5 | 49.0 | 7,636 |
| sedationSignal | 56 | 26.7 | 20.6 | 1,359 |
| drug withdrawal syndromeSignal | 77 | 10.9 | 8.8 | 688 |
| weight increasedSignal | 91 | 5.1 | 4.1 | 296 |
| off label useSignal | 306 | 4.4 | 3.9 | 822 |
| somnolenceSignal | 59 | 3.7 | 2.8 | 112 |
| insomniaSignal | 76 | 3.6 | 2.9 | 139 |
| feeling abnormalSignal | 61 | 3.2 | 2.5 | 90 |
| weight decreasedSignal | 68 | 3.0 | 2.4 | 92 |
| decreased appetiteSignal | 53 | 2.8 | 2.2 | 62 |
| dizzinessSignal | 89 | 2.2 | 1.8 | 60 |
| anxietySignal | 50 | 2.2 | 1.7 | 32 |
| vomiting | 64 | 1.7 | 1.3 | 18 |
| nausea | 70 | 1.1 | 0.9 | 1 |
| fatigue | 56 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.